Semaglutide for reducing the risk of major adverse cardiovascular events in people with cardiovascular disease and overweight or obesity

  • Technology appraisal guidance
  • TA1152
  • Published: 

Suggested remit: To appraise the clinical and cost effectiveness of Semaglutide within its marketing authorisation for treating cardiovascular disease.

This page was last updated: